Neurodegenerative Diseases Drugs Market Sees Rapid Innovation in Treatment Options for Patients

Neurodegenerative Diseases Drugs Market

The neurodegenerative diseases drugs market is experiencing a robust transformation driven by scientific innovation, biomarker-based drug development, and urgent healthcare needs. According to recent insights published by Persistence Market Research, the global market size is projected to reach US$ 85.0 Bn by 2032, growing at a CAGR of 5.5% from US$ 58.4 Bn in 2025. The market is benefiting from a transition from symptomatic treatment approaches to disease-modifying and targeted immunomodulatory therapies. The rising burden of Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis is further boosting this evolution.

North America leads the global landscape, accounting for over 51.8% of the market share in 2025. This dominance stems from the region’s accelerated drug approvals, regulatory flexibility, and high healthcare investment. Multiple sclerosis is the leading segment by disease indication, thanks to strong advocacy networks, abundant biomarker support, and the availability of multiple approved immunotherapies. Meanwhile, immunomodulators are expected to be the top drug class, representing around 43.5% of the market in 2025, due to their targeted action on neuroinflammatory pathways.

Key Highlights from the Report

• Immunomodulators expected to capture 43.5% of the market share in 2025.
• North America remains the top region, backed by regulatory acceleration and diagnostic investment.
• Shift from symptomatic relief to biomarker-enabled early interventions fuels innovation.
• Disease-modifying therapies for multiple sclerosis lead adoption across end-users.
• Development of treatments for non-motor Parkinson’s symptoms is opening new frontiers.
• Advancements in stem cell-based therapies are pushing drug discovery pipelines forward.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35538

Market Segmentation: Drug Classes and Disease Indications

The market is divided by drug class into immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others. Immunomodulators, which can target neuroinflammation and immune dysregulation, are the dominant class. These drugs are vital in managing multiple sclerosis, which has a well-defined autoimmune nature. Dopamine agonists are seeing rising adoption in Parkinson’s treatment due to their reduced side effects compared to levodopa and their suitability for early intervention.

From a disease indication perspective, the market segments into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Spinal Muscular Atrophy (SMA), and others. Multiple sclerosis is projected to account for 62.6% of the market share in 2025, driven by decades of therapeutic innovation and accessible diagnostic markers. Alzheimer’s, while trailing in current approvals, is gaining traction as precision-based drugs enter the market and attract large-scale funding from governments and nonprofits.

Regional Insights: Global Footprint of Market Expansion

In North America, especially the United States, the market is supported by public insurance schemes, such as Medicare, and regulatory breakthroughs like the approval of Leqembi by the FDA. The CMS’s decision to expand coverage has acted as a catalyst for innovation and payer engagement, encouraging pharma players to bring newer drugs to market.

Europe shows slower uptake compared to the U.S. due to cost-effectiveness assessments and lengthy reimbursement processes. However, initiatives like the Innovative Health Initiative and the European Platform for Neurodegenerative Diseases (EPND) are helping build a more integrated R&D and regulatory environment across EU member states.

In the Asia Pacific, Japan is leading with swift regulatory approvals and national insurance coverage for advanced treatments. China and South Korea are emerging as innovation hubs, fueled by government-supported health agendas and increasing local biopharmaceutical capabilities. The Healthy China 2030 initiative, in particular, is accelerating drug trials and global expansion for Chinese firms.

Market Drivers:

A pivotal driver is the growing emphasis on early diagnosis. The increasing use of PET imaging, CSF biomarkers, and blood tests has enabled early-stage treatment eligibility, notably in Alzheimer’s. Drugs like lecanemab and donanemab are approved specifically for use in the mild cognitive impairment stage, emphasizing the need for early intervention infrastructure. Payers are showing greater willingness to reimburse such targeted treatments, bolstering the commercial viability of disease-modifying drugs.

Market Restraints

Despite innovation, reimbursement challenges and diagnostic gaps present serious hurdles. Clinicians continue to rely on symptomatic treatments due to cost concerns and the lack of broad access to biomarker tests. A 2024 Alzheimer’s Association survey revealed that less than 30% of U.S. neurologists routinely use advanced diagnostic tools. This limits the real-world impact of approved therapies, stalling adoption and investor confidence.

Market Opportunities

Stem cell therapy is reshaping the future of neurodegenerative treatment. By promoting neural regeneration, stem cell approaches are not only symptom-modifying but also disease-reversing in nature. Companies are investing in combination therapies involving immunomodulators and regenerative agents. BlueRock Therapeutics, for instance, began Phase 2 trials of its iPSC-derived therapy for Parkinson’s in 2024, with promising results that may transform disease management.

Reasons to Buy the Report:

  1. Comprehensive breakdown of current and forecasted market trends across major regions.

  2.  In-depth analysis of leading drug classes and disease indications.

  3. Coverage of latest regulatory changes, reimbursement models, and technological advances.

  4. Profiles of leading pharmaceutical companies with pipeline status and strategic initiatives.

  5. Insights from Persistence Market Research enabling investment and business strategy decisions.

Frequently Asked Questions (FAQs):

• How big is the neurodegenerative diseases drugs market?
• What is the projected growth rate of the neurodegenerative diseases drugs market?
• Who are the key players in the global market for neurodegenerative diseases drugs?
• What is the market forecast for neurodegenerative diseases drugs by 2032?
• Which region is estimated to dominate the industry through the forecast period?

Company Insights

The global neurodegenerative diseases drugs market is served by a mix of pharmaceutical giants and innovative biotech firms, each contributing to the dynamic landscape through R&D and strategic partnerships. Leading players include:

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S
• Mitsubishi Tanabe Pharma Corporation

Recent Developments:
• In July 2025, Klotho Neurosciences received FDA Orphan Drug Designation for KLTO-202, targeting ALS with a secreted-Klotho gene therapy approach.
• In March 2025, Alpha Cognition Inc. officially launched ZUNVEYL, a new drug for mild to moderate Alzheimer’s, aiming to enhance accessibility and patient quality of life.

Conclusion:

The neurodegenerative diseases drugs market is in a critical phase of transformation. A convergence of early diagnosis, regulatory support, biologic innovation, and targeted immunotherapies is reshaping how neurodegenerative disorders are treated. Despite challenges around reimbursement and diagnostic infrastructure, there is growing momentum in stem cell research, precision therapies, and regional investment that will define the next wave of breakthroughs.

Stakeholders—ranging from big pharma to health policymakers—need to act strategically, embracing both scientific and systemic innovation. The opportunity is not just commercial but profoundly humanitarian: to change the trajectory of some of the most devastating neurological conditions facing aging populations worldwide.

Read More Related Reports:

Emergency Cricothyrotomy Kits Market

Soft Skeletal Implants Market

Persistence Market Research

Persistence Market Research

At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviors, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.